Clinical trials evaluating the EpCAM-targeting mAb adecatumumab for breast cancer treatment showed that the probability of tumor progression was significantly lower in patients with tumors expressing high levels of EpCAM and receiving a high dose [29,34]. Here, EPCAM is linked to breast carcinoma.